SG/CALL/VERTEX PHARMACEUTICALS/350/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 20:38:41 14/06/2024 BST | ||
| 12.85 EUR | +2.55% |
|
| Current month | +21.69% | ||
| 1 month | +55.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 12.85 | +2.55% |
| 13/06/24 | 12.53 | +1.87% |
| 12/06/24 | 12.3 | -5.24% |
| 11/06/24 | 12.98 | -1.74% |
| 10/06/24 | 13.21 | +0.61% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 08:38 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ80FA |
| ISIN | DE000SQ80FA4 |
| Date issued | 13/02/2023 |
| Strike | 350 $ |
| Maturity | 20/09/2024 (97 Days) |
| Parity | 10 : 1 |
| Emission price | 3.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.21 € |
|---|---|
| Lowest since issue | 2.91 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant